Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 10,730 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
507
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 345 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Bleeding Assessment Tool (BAT)

NCT07560007
Conditions
Bleeding Disorder, Von Willebrand Disease (VWD)
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Multiple Myeloma
Interventions
IBI3003
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more
Conditions
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
Interventions
Elotuzumab, pomalidomide, dexamethasone, Anti-LAG-3, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-TIGIT, Anti-TIGIT + Pomalidimide + Dexamethasone
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Terminated No phase listed Observational Accepts healthy volunteers Results available

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

NCT01326728
Conditions
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma, Non-Hodgkins Lymphoma
Interventions
Allogeneic stem cell transplant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoblastic Leukemia, Acute
Interventions
NK Cell Infusion
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Interventions
Nadunolimab, Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anemia
Interventions
Epoetin Alfa
Drug
Lead sponsor
Mehrotra, Anita, M.D.
Individual
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Myelocytic, Acute
Interventions
Apheresis, Stem Cell Transplant
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
Interventions
XmAb14045
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Jacksonville, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Conditions
Beta-Thalassemia
Interventions
No Intervention
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2043
U.S. locations
6
States / cities
Oakland, California • Palo Alto, California • Minneapolis, Minnesota + 3 more
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Conditions
Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma
Interventions
Number of Participants with massive blood transfusion
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Jacksonville, Florida
Conditions
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
Interventions
CTX110
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 18 more
Conditions
Acute Myeloid Leukemia
Interventions
Universal Donor Natural Killer Cells
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
GS-9219
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Interventions
Ixazomib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BMS-247550
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 15 more
Conditions
Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anidulafungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Durham, North Carolina + 1 more
Conditions
Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Prexasertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
B Cell Leukemia, B Cell Lymphoma
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 24 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio